ArticleDiagnostic pathology2026
Clinicopathological analysis of 19 cases of mixed gangliocytoma-pituitary neuroendocrine tumors.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mixed gangliocytoma-pituitary neuroendocrine tumors (PitNETs) occurring in the sellar region are extremely rare neoplasms. To improve the understanding of these tumors and guide clinical diagnosis, a comprehensive retrospective study analyzing clinical manifestations and pathological morphology in 19 cases of sellar mixed gangliocytoma-PitNETs was conducted. A total of 19 mixed gangliocytoma-PitNETs patients from Huashan Hospital, Fudan University (January 2013 – September 2025) were enrolled. Clinical manifestations, radiological characteristics, histological features, immunohistochemical and molecular analyses were systematically evaluated. This tumor is more common in women, and the cohort comprised 17 females and 2 males, aged 28–70 years (mean 45.3 ± 12.1). Acromegaly was the most common clinical presentation (6/19, 31.59%). Preoperative endocrine testing revealed elevated Insulin-like Growth Factor-1 (IGF-1) levels in the majority of patients (12/19, 63.16%). MRI demonstrated round or oval-shaped mass lesions with marked contrast enhancement. Histologically, PitNETs components exhibited diffuse sheets of small, uniform round-to-ovoid cells, accompanied by focal large gangliocyte-like cells. Immunohistochemistry revealed Pit-1 positive in all 19 cases and CAM5.2 highlights fibrous bodies in 18 cases while 1 case perinuclear positive. According to the 2022 WHO criteria, 18 cases (18/19, 94.74%) diagnosed as high-risk sparse granular somatotroph PitNETs and 1 case (1/19, 5.26%) diagnosed as dense granular somatotroph PitNETs. Molecular analyses of GNAS R201 and BRAF V600E mutations in 19 cases showed wild-type. All patients underwent transsphenoidal surgery (TSS). Postoperative follow-up (mean 67.2 ± 36.0 months, range 3–129) revealed no tumor recurrence. For PitNETs with gangliocytic components, histopathological evaluation must rigorously assess adenoma lineages, given their frequent association with high-risk Pit-1-lineage tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.